IL-6 as a Measure of Peripheral Inflammation Is More Often Elevated in Cognitively Impaired Individuals
A recent open‑access study of 514 Canadian seniors examined peripheral inflammation using IL‑6 and C‑reactive protein. The analysis revealed that elevated IL‑6 levels were present in 12% of cognitively normal participants but rose sharply to 36‑55% among Alzheimer’s, mixed dementia, and vascular mild cognitive impairment groups. Age, higher body‑mass index and greater white‑matter hyperintensity scores were the strongest determinants of heightened inflammation. The authors caution that while inflammation is common in cognitive impairment, therapeutic targeting remains unproven.
Lonza Boosts Advanced Synthesis Capabilities for Bioconjugates
Lonza has expanded its advanced synthesis portfolio to provide end‑to‑end support for antibody‑drug conjugates (ADCs) and other bioconjugates. The company fully integrated the Synaffix‑derived ADC platform—including GlycoConnect® conjugation, HydraSpace® spacers and toxSYN® linker payloads—into its services. A new dual‑payload ADC...
Machine Learning Streamlines the Complexities of Making Better Proteins
Researchers at UC Berkeley and the Arc Institute unveiled MULTI‑evolve, a machine‑learning framework that predicts how multiple amino‑acid mutations affect protein function in a single experimental round. The workflow first estimates single‑mutation effects, then measures pairwise interactions, and finally trains...
Stronger Scents and Healthier Crops: Unlocking Plants' Hidden Potential Through Precision Gene Editing
Researchers at Hebrew University used a virus‑based CRISPR/Cas9 system to edit the regulatory domain of the HMGR enzyme, removing its metabolic brake and dramatically increasing terpenoid production. The edit boosted scent intensity and flower size in petunias and enhanced flavor‑related...
A New Method to Decode How DNA 'Switches' Control Gene Activity
Researchers unveiled e2MPRA, a massively parallel reporter assay that simultaneously measures regulatory activity, chromatin accessibility, and H3K27ac modifications across thousands of cis‑regulatory elements. Validated on ~10,000 synthetic and native sequences, the method links single‑base mutations to multi‑layered gene‑regulatory outcomes. The...
From Skin Biopsy to iPS Cell Proposals: Emails Involving George Church’s Personal Genome Project and Jeffrey Epstein
Recent court‑released Epstein files contain emails that link Harvard professor George Church’s Personal Genome Project to Jeffrey Epstein. The correspondence documents a skin‑biopsy taken from Epstein, proposals to generate induced pluripotent stem (iPS) cells, and even CRISPR editing ideas, with...
A Circulating Inflammation Suppressor Decreases Mortality
Researchers used Mendelian randomization to demonstrate that the inflammatory cytokine IL6 directly increases all‑cause mortality, while its soluble receptor IL6R has the opposite effect. Elevated circulating IL6R was linked to lower risk of lung cancer, diabetes, stroke and coronary artery...
Obesity Biotech Verdiva Plans Big Year of Data, Explores Deals
Verdiva Bio, an obesity‑focused biotech, is gearing up for a data‑heavy 2026, with Phase 2 results for its lead long‑acting peptide slated for the third quarter. The company is also courting strategic partnerships, eyeing potential deals with major pharma players after...
Tradipitant
Vanda Pharmaceuticals received FDA approval for tradipitant (Nereus®), an oral selective NK1 receptor antagonist, to treat motion‑induced nausea and vomiting. The approval marks the first new drug for motion sickness in more than four decades, highlighting a significant regulatory milestone....
Redefining Obesity Treatment Beyond GLP-1 Limits
BioSpace’s Denatured podcast featured Verdiva Bio’s R&D head Jane Hughes and MitoRx CEO Jon Rees discussing next‑generation obesity therapies that move beyond the limitations of GLP‑1 agonists. They highlighted how GLP‑1 treatments can cause muscle loss and suffer from poor...
Biogen Stops Part of an MS Trial; Merck Reports More Enflonsia Data
Biogen announced it is halting the combination‑therapy arm of its multiple sclerosis (MS) trial after interim data showed insufficient efficacy and safety concerns. The decision pauses enrollment in the experimental regimen while the company continues evaluating its monotherapy components. Meanwhile,...
Valneva’s Lyme Disease Vaccine Offers Beacon of Hope Amid 2025 Sales Dip
Valneva reported a 3.3% decline in product sales to €157.9 million in 2025, driven primarily by regulatory suspensions of its chikungunya vaccine Ixchiq in the US and UK. Despite the sales dip, total revenue rose to €174.7 million, buoyed by a licensing...
Pembrolizumab-Induced Adrenal Insufficiency: Recognizing and Managing a Diagnostic Challenge in Adjuvant NSCLC Therapy
Pembrolizumab used as adjuvant therapy for NSCLC can cause central adrenal insufficiency, presenting with nonspecific fatigue, nausea, and hyponatremia. In a 67‑year‑old patient, a markedly low morning cortisol and suppressed ACTH confirmed the diagnosis within ten weeks of treatment. Prompt...
2024-2025 COVID-19 Vaccines Provided Moderate Protection Against JN.1 Variants
A recent JAMA Network Open case‑control study of 8,493 hospitalized adults shows that 2024‑2025 COVID‑19 vaccines provided moderate protection against the JN.1 lineage, with overall effectiveness of 40% against hospitalization and up to 52% after 90‑179 days. Updated Moderna and...
Treg Pioneer Bluestone Joins Vie Ventures as It Builds Autoimmune Portfolio
Vie Ventures has hired immunology veteran Jeff Bluestone to strengthen its autoimmune‑focused venture portfolio. Bluestone, founder of the Immune Tolerance Network and former CEO of the Parker Institute for Cancer Immunotherapy, previously co‑founded Sonoma Biotherapeutics and created Tzield teplizumab, the...
LPM-5140276 Shows Enhanced Antitumor Efficacy in Combination with RMC-4550
Researchers reported that the novel KRAS G12D inhibitor LPM-5140276 markedly improves antitumor activity when paired with the SHP2 inhibitor RMC-4550. The combination demonstrated synergistic tumor regression in preclinical models of pancreatic and colorectal cancers harboring KRAS G12D mutations. Data suggest enhanced pathway...
FNIH Biomarkers Consortium Study Shows “Clock Model” Blood Test Can Predict Onset of Alzheimer’s Symptoms Years in Advance
The FNIH Biomarkers Consortium unveiled a “clock model” that uses a single blood test to forecast Alzheimer’s disease symptom onset 3‑4 years before clinical presentation. The model aggregates plasma biomarkers into a temporal trajectory, and a new web‑based visualization tool...
ViiV Healthcare Reports P-III (LATITUDE) Trial of Cabenuva in Adherence-Challenged HIV Patients
ViiV Healthcare presented results from the Phase III LATITUDE trial evaluating Cabenuva, a long‑acting injectable of cabotegravir and rilpivirine, in 453 adults with adherence challenges. Among 306 virally suppressed participants, the quarterly injection reduced cumulative regimen failure to 22.8% versus...
High Risk Research: HHS Should Publicly Share More Information on How Risk Is Assessed and Mitigated
The Government Accountability Office (GAO) reports that the Department of Health and Human Services (HHS) conducts risk assessments for gain‑of‑function research but does not consistently share those findings with the public. While the research has expanded understanding of pathogen transmission,...
Oral Nanozyme Treats Colitis-Linked Mental Disorders via Gut-Brain Axis
Researchers at Yangzhou and Nanjing Universities have created an oral polysaccharide‑engineered nanozyme—fucoidan‑cerium nanocomplexes (FucCeNCs)—to treat colitis‑associated anxiety and depression. The nanocomplex combines cerium’s superoxide dismutase‑like activity with fucoidan’s prebiotic properties, enabling simultaneous reactive oxygen/nitrogen species scavenging and gut microbiota modulation....
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
CRISPR Therapeutics shares rose over 12% after reporting Q4 2025 earnings that showed a larger‑than‑expected loss and minimal recognized revenue. The company’s flagship therapy CASGEVY generated $54 million in sales, but under its revenue‑sharing deal with Vertex only $0.86 million was recorded. CRISPR...
STAT+: What to Expect From Gossamer Bio’s Late-Stage Lung Disease Study
Gossamer Bio is set to announce results from its Phase 3 trial in pulmonary arterial hypertension (PAH) before the end of February. The readout follows a Phase 2 study that delivered modest, sub‑par efficacy, which the company attributes to an...
Partial Reprogramming of Neurons Encoding Memory Improves Cognitive Function in Aged Mice
Researchers applied cyclic OSK (Oct4‑Sox2‑Klf4) gene therapy to memory‑encoding neurons in aged mice, achieving partial cellular reprogramming without full pluripotency. The intervention reversed senescence‑related gene expression, restored youthful epigenetic patterns, and normalized synaptic plasticity in both hippocampal and prefrontal engrams....
Pharma Pulse: FDA’s Moderna Reversal and Eli Lilly’s $100 Million IL-6 Bet
The FDA has reversed its earlier refusal-to-file and will review Moderna’s seasonal mRNA influenza vaccine, with a decision slated for August 5, 2026. Moderna now seeks full approval for adults aged 50‑64 and accelerated approval for those 65 and older. Meanwhile, Eli Lilly...
Antioxidant Nanoparticles May Protect Male Fertility During Chemotherapy
A preclinical study published in Reproductive and Developmental Medicine found that combining melatonin with zinc oxide nanoparticles mitigates cyclophosphamide‑induced reproductive toxicity in male rats. The antioxidant duo restored testosterone and luteinizing hormone levels, lowered oxidative stress markers, and preserved spermatogenic...
MSD and Mayo Clinic Team up to Advance AI in Drug Development
Merck (MSD) and Mayo Clinic have launched a research partnership that blends Mayo's Platform architecture and multimodal clinical‑genomic data with MSD's virtual‑cell technologies. The collaboration gives MSD direct access to de‑identified imaging, lab, molecular and notes data to train and...
MSD and Mayo Clinic Team up to Advance AI in Drug Development
Merck & Co (MSD) and Mayo Clinic have launched a research partnership that leverages AI, advanced analytics, and multimodal clinical‑genomic data to accelerate drug discovery and precision medicine. The collaboration merges Mayo’s Platform architecture and de‑identified datasets—including imaging, labs, molecular...
Verily Launches Self-Serve Access to Pre Platform with New Segmed and RefinedScience Datasets
Alphabet’s Verily has introduced a free, self‑serve Standard tier for its Pre precision‑health platform, allowing researchers to access the Exchange catalog and Workbench environment with just a Google account. The rollout adds three high‑impact datasets: a single‑cell AML cohort from...
UV Red Flag: Color-Changing ‘Living’ Material Warns of Harmful Radiation
Researchers at the Technical University of Munich have created a bio‑hybrid coating that visibly signals UV‑A exposure by turning from green to red. The sensor embeds dry Escherichia coli cells loaded with the photoconvertible protein mEosFP, which undergoes an irreversible...
Gold@MnFe‐Prussian Blue Analog Yolk@Shell Nanoparticles for Light‐Triggered and pH‐Sensitive Drug Release
Researchers have engineered Au@MnFe‑Prussian Blue Analog yolk‑shell nanoparticles that combine a hollow cavity with a functional shell for biomedical use. The synthesis creates a ~75 nm interior, achieving roughly 50% loading efficiency for the chemotherapeutic doxorubicin. Partial etching and redeposition of...
Achieving High‐Efficiency Type I Multimodal Photosensitizers via a Synergistic Rigidity‐Flexibility Strategy for Hypoxia‐Resistant Tumor Therapy
Researchers introduced a donor‑acceptor (D‑A) molecular design that couples a rigid coplanar backbone with flexible side chains, dramatically raising near‑infrared molar extinction and fluorescence brightness. The resulting phenothiazine‑based photosensitizer, EL‑TPO2F, also exhibits strong type‑I reactive oxygen species (ROS) production and...
Swedish CubaseBio Emerges From Stealth with €5.9 Million to Scale Volumetric DNA Microscopy
Swedish startup CubaseBio has emerged from stealth after raising €5.9 million in blended financing – a €2 million European Innovation Council grant plus €3.9 million from Voima Ventures, Nordic Science Investments, Illumina Ventures and other life‑science investors. The capital will accelerate development of...
9 Companies Hiring Now in Pennsylvania
Pennsylvania’s Greater Philadelphia corridor remains a biotech hotbed, housing over 1,200 life‑science firms including AstraZeneca, GSK and Johnson & Johnson. Eli Lilly announced a new injectable weight‑loss manufacturing plant in the Lehigh Valley, projected to create roughly 850 jobs by 2031....
Shape‑conformal 3D Frameworks Enable Full‑surface Neural Organoid Electrophysiology
If you’re interested in organoid biology and/or 3D bioelectronics, then check out our paper published today in Nature Biomedical Engineering, titled ‘Shape-conformal porous frameworks for full coverage of neural organoids and high-resolution electrophysiology,’ at https://t.co/Y7MzvRQKTm. This work introduces a technology...
Extending Scientific Rigor From Bench to Boardroom
Researchers who launch biotech startups often abandon evidence‑based decision‑making once they enter the boardroom, falling prey to technology myopia, base‑rate neglect, and confirmation bias. Their lack of formal training in commercialization, financial modeling, and competitive analysis amplifies these pitfalls, leading...
Scientists Develop the World’s Tiniest Wireless Brain Implant
Scientists at Cornell University have created a wireless brain implant so small it can sit on a grain of salt, yet still record and transmit neural activity. The device uses light‑based optics for power and data, eliminating bulky wires and...
On Its 15th Anniversary, Foresite Capital Looks Ahead
Foresite Capital marked its 15th anniversary by projecting a resurgence in biopharma venture capital, anticipating a year‑over‑year rise in financings and IPOs starting in 2026. The firm highlighted a surge to $149 billion in biopharma VC dollars in 2025 and a...
Reversing Nerve Cell Age to Combat ALS, Alzheimer’s
Super proud of Dr. Kelly Rich, senior postdoc in our lab who's pioneering nerve cell epigenetic age reversal to treat diseases such as ALS and Alzheimer's 🪨⭐️ https://open.spotify.com/episode/7nWkEH5li36oW9monEIG8B
EBV DNA Linked to Multiple Autoimmune Diseases in 800k Genomes
🆕@Nature Genome sequencing of >800,000 people finds Epstein-Barr virus reads and their association with other autoimmune diseases besides multiple sclerosis, including type 1 diabetes, inflammatory bowel disease, and hypothyroidism https://t.co/FKCV4OInT5
Altesa Secures $75M for Lung Drug, Led by Ex‑Trump Official
Altesa, run by former Trump official, raises $75M for well-traveled lung drug https://t.co/bUx5dcvNJy by @gwendolynawu #biotech #startups
New Drug Development Reforms Aim to Match China
These proposed reforms to pre-clinical drug development and to smoothing the transition to first-in-human studies could be the most consequential steps toward leveling the playing field with China. https://t.co/oVY6N3xo9Y
Adding Fragmentomics Boosts GRAIL’s Multicancer Detection Accuracy
The most used multicancer early detection (MCED) blood test (liquid biopsy) uses methylation (GRAIL). But combining that with DNA fragmentomics, as reported today @NatureCancer, improves early detection https://t.co/VkNDR4XuW3
FDA Proposes Single Pivotal Trial as Approval Standard
FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals https://t.co/ADRb1miphf by Kristin Jensen #biotech
Group 3 Medulloblastoma Shows Diverse Lipid Dependencies
Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma https://t.co/tpjJiRa08t https://t.co/z7aIYerTqO
Intronic Reads in Bulk RNA‑seq: Common and Multi‑Faceted
Why are there intronic reads in your bulk RNA-seq data? You're not alone—it's common, and the reasons are more layered than you think. Let’s break it down. 🧵 https://t.co/SNJnohqHUM
Former Psilocybin Trial Participant Shocked by New Findings
"I took part in a 2012 psilocybin trial. What I’m seeing now horrifies me" https://t.co/T1BLv6n59X via @statnews
Blood P‑tau217 Test Predicts Alzheimer’s Symptoms 20 Years Ahead
Predicting when symptoms of Alzheimer's disease will occur with elevated p-tau217 blood test and a person's age, even 20+ years in advance @NatureMedicine https://t.co/EYaGglBh1H
Gossamer Lung Trial and ProMis Alzheimer Therapy Spotlight
This week's Biotech Scorecard newsletter: -- What to expect from $GOSS Gossamer Bio’s late-stage lung disease study -- A better, safer Alzheimer’s treatment? ProMis $PMN takes its shot https://t.co/YaA8kvUR4Z
Profusa Enables Real‑Time Tissue Biochemistry Monitoring
👍Profusa is my pick for 2026. Fascinating technology to measure real time tissue biochemistry. This is a fundamental shift from blood to tissue to shine a new light on cellular status and metabolism. https://t.co/gfduGvgJTX @ProfusaInc #medicine $PFSA #diabetes
INSM Projects 2026 Brinsupri Sales Minimum $1B
$INSM guides to 2026 Brinsupri sales of "at least $1B" in line with consensus. https://t.co/o7JhPKU3m1